Company profile: OncoSynergy
1.1 - Company Overview
Company description
- Provider of Resistance Mechanism Inhibitors (RMIs) targeting multiple cancer-driving pathways to address resistance, including OS2966, a monoclonal antibody against CD29 to inhibit cancer growth, invasiveness, and resistance. Conducting a Phase 1 trial in recurrent glioblastoma evaluating OS2966 delivered directly to the brain via convection-enhanced delivery.
Products and services
- Resistance Mechanism Inhibitors (RMIs): A mechanism-based therapeutic strategy that simultaneously targets multiple hallmarks of cancer progression, addressing resistance to conventional and targeted therapies, with dramatic preclinical efficacy as monotherapy
- OS2966: A clinical-stage monoclonal antibody targeting CD29 to inhibit cancer growth, invasiveness, and resistance, currently under Phase 1 evaluation for recurrent glioblastoma
- Recurrent Glioblastoma Phase 1 Trial: An intracranial study assessing OS2966 safety and tolerability when delivered directly to the brain using convection-enhanced delivery in patients with recurrent high-grade glioma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OncoSynergy
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Exact Sciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including Cologuard, a non-invasive at-home stool-based colorectal cancer screening test for individuals 45+, Riskguard hereditary cancer testing, Oncotype DX Breast Recurrence Score to assess recurrence and guide treatment for ER+/HER2- breast cancer, OncoExTra genomic profiling for therapy selection in advanced/metastatic cancer, and under-development Breast Radiation Score and colorectal cancer blood test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Sciences company profile →
MabVax Therapeutics
HQ: United States
Website
- Description: Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MabVax Therapeutics company profile →
NxThera
HQ: United States
Website
- Description: Provider of medical technologies for endourology conditions, including benign prostatic hyperplasia (BPH). The company's minimally invasive vapor therapy platform is designed to measurably improve urinary flow and patient quality of life; BPH affects more than 32 million men in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NxThera company profile →
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OncoSynergy
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OncoSynergy
2.2 - Growth funds investing in similar companies to OncoSynergy
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OncoSynergy
4.2 - Public trading comparable groups for OncoSynergy
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →